| Q27014978 | 50 Years of progress in the systemic therapy of non-small cell lung cancer |
| Q28267987 | A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer: implications for adjuvant therapy |
| Q33703679 | Adjuvant Therapy Choices in Patients With Resected Non-Small-Cell Lung Cancer: Correlation of Doctors' Treatment Plans and Relevant Phase III Trial Data |
| Q35584223 | Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions |
| Q38831491 | Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward? |
| Q36060352 | Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer |
| Q35581371 | Adjuvant chemotherapy after complete resection for early stage NSCLC. |
| Q37217748 | Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC) |
| Q37270934 | Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review. |
| Q34143336 | Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? |
| Q24187439 | Adjuvant chemotherapy for resected early-stage non-small cell lung cancer |
| Q36780586 | Adjuvant chemotherapy for resected non-small cell lung cancer. |
| Q35771994 | Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research |
| Q33546241 | Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data |
| Q35076202 | Adjuvant therapy for resected non-small cell lung cancer |
| Q36157288 | Adjuvant therapy for resected non-small-cell lung cancer: past, present, and future |
| Q35783036 | Adjuvant therapy for resected non-small-cell lung cancer: recent advances, emerging agents, and lingering questions. |
| Q35142848 | Adjuvant therapy in completely resected non-small-cell lung cancer |
| Q33999146 | Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial |
| Q34031225 | Advances in adjuvant systemic therapy for non-small-cell lung cancer |
| Q47135740 | An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer |
| Q42323728 | Chemosensitivity of lung cancer: Differences between the primary lesion and lymph node metastasis |
| Q77344432 | Chemotherapy in Stage I/II NSCLC and projects of the EORTC-Lung Cancer Group for Early Stage Lung Cancer |
| Q35543226 | Chemotherapy in metastatic and locally advanced non‐small cell lung cancer |
| Q35017988 | Chemotherapy of non-small cell lung cancer in the elderly |
| Q79246211 | Cisplatin-Based Adjuvant Chemotherapy in Resected Non–Small-Cell Lung Cancer |
| Q52770412 | Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. |
| Q36993644 | Combined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citations |
| Q37343460 | Comparison of concurrent chemoradiotherapy versus sequential radiochemotherapy in patients with completely resected non-small cell lung cancer |
| Q35017967 | Consensus conference on medical treatment of non-small cell lung cancer: adjuvant treatment |
| Q35017957 | Consensus development conference on the medical treatment of non-small cell lung cancer: treatment of the early stages |
| Q80510512 | DNA-binding agents |
| Q36617872 | Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancer |
| Q34384459 | Development of treatment strategies in locally advanced non-small cell lung cancer (take home messages). |
| Q46411995 | EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer |
| Q46039810 | EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. |
| Q80100754 | EGFR: a prognostic and/or a predictive marker? |
| Q50128100 | Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. |
| Q94487044 | Easier node dissection after chemoradiotherapy for lung cancer with collagen insertion at mediastinoscopy |
| Q33705213 | Epithelial-mesenchymal transition-associated secretory phenotype predicts survival in lung cancer patients |
| Q75211200 | Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection |
| Q38568190 | Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). |
| Q36049618 | Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. |
| Q33621874 | Immunological Aspect of Radiation-Induced Pneumonitis, Current Treatment Strategies, and Future Prospects |
| Q36197030 | Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer |
| Q79278145 | Induction Therapy for Early-Stage Lung Cancer? The Rationale Behind the Question |
| Q94093273 | Lung cancer |
| Q34982142 | Lung cancer--where are we today? Current advances in staging and nonsurgical treatment. |
| Q29620125 | MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer |
| Q44796372 | Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents |
| Q34951884 | Multi-modality treatment of non-small cell lung cancer |
| Q35008704 | Neoadjuvant and adjuvant therapy of non-small cell lung cancer |
| Q34447477 | Neoadjuvant strategies for non-small cell lung cancer. |
| Q89574416 | Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients |
| Q40040718 | Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. |
| Q60445024 | Place des traitements adjuvants et néo-adjuvants dans les cancers non à petites cellules (CBNPC) de stade précoce |
| Q57569751 | Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients |
| Q52959828 | Post-operative adjuvant thoracic radiotherapy for patients with completely resected non-small cell lung cancer with nodal involvement: outcome and prognostic factors. |
| Q26830376 | Post-operative radiation therapy |
| Q37456466 | Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer |
| Q36180682 | Postoperative adjuvant therapy for completely resected early-stage non-small cell lung cancer |
| Q37016941 | Postoperative radiation therapy for non-small cell lung cancer and thymic malignancies |
| Q35584905 | Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution |
| Q34384406 | Postoperative radiotherapy in localized non-small cell lung cancer |
| Q73483272 | Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery |
| Q61447756 | Predictive risk factors for lymph node metastasis in patients with resected non-small cell lung cancer: a case control study |
| Q36694678 | Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer |
| Q36614079 | Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study |
| Q64235297 | Prognostic value of adjuvant therapy in T4 non-small cell lung cancer: An inverse probability of treatment weighting analysis |
| Q54974208 | Prophylactic Cranial Irradiation in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
| Q74755318 | Radiation Therapy Oncology Group. Research Plan 2002-2006. Major research objectives |
| Q30857091 | Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer |
| Q38390158 | Radiotherapy for single station N2 NSCLC. |
| Q84567479 | Recent publications by ochsner authors |
| Q47593311 | Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience |
| Q33698439 | Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer |
| Q24633254 | Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data |
| Q47602832 | Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer |
| Q34810785 | Selection and description of cancer clinical trials participants--science or happenstance? |
| Q37121332 | Sequencing postoperative radiotherapy and adjuvant chemotherapy in non-small cell lung cancer: unanswered questions on the not evidence-based approach |
| Q81505455 | Should adjuvant chemotherapy become standard treatment in all patients with resected non-small-cell lung cancer? |
| Q34569366 | Staging classification of lung cancer. A critical evaluation |
| Q80100820 | Surgical patterns of care in operable lung carcinoma treated with radiation |
| Q34447470 | Surgical treatment of stage III non-small cell lung cancer |
| Q36482648 | Survival after surgery in stage IA and IB non-small cell lung cancer. |
| Q63997730 | Survival impact of postoperative therapy modalities according to margin status in non-small cell lung cancer patients in the United States |
| Q37158881 | Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer |
| Q35536290 | The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. |
| Q89848920 | The Phenoxyphenol Compound 4-HPPP Selectively Induces Antiproliferation Effects and Apoptosis in Human Lung Cancer Cells through Aneupolyploidization and ATR DNA Repair Signaling |
| Q73308315 | The dream is almost over...don't worry, look ahead |
| Q35544772 | The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer |
| Q44138321 | The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer |
| Q79341735 | The possible use of uniform PORT doses is important in the SEER analysis, but undetected selection bias remains an issue |
| Q41829997 | The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer |
| Q37194315 | The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer |
| Q44365541 | The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database |
| Q34461776 | The role of chemotherapy in early non-small-cell lung cancer management. |
| Q77225053 | The role of chemotherapy in early stage of non-small cell lung cancer |
| Q36308285 | The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy |
| Q36858192 | The role of surgery in the treatment of stage III non-small-cell lung cancer |
| Q34325455 | The single institutional outcome of postoperative radiotherapy and concurrent chemoradiotherapy in resected non-small cell lung cancer |
| Q34657144 | The use of pharmacogenomics for selection of therapy in non-small-cell lung cancer |
| Q37642455 | Therapeutic management options for stage III non-small cell lung cancer |
| Q34569384 | Therapy for stage I and stage II non-small cell lung cancer |
| Q64980569 | Transmembrane-4 L-six family member-1 (TM4SF1) promotes non-small cell lung cancer proliferation, invasion and chemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis. |
| Q35551162 | Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents |
| Q36796569 | Update in lung cancer 2006 |
| Q48295235 | Using circulating tumor cells to evaluate the efficacy of irreversible electroporation for unresectasble pancreatic cancer. |
| Q34278715 | What's new in general thoracic surgery |
| Q79383672 | [Adjuvant chemotherapy for stage IB non small cell lung cancer: the standard of care?] |
| Q84566595 | [Radiation therapy of lung carcinoma] |
| Q81205224 | [Surgical treatment of non-small cell lung cancer] |